Visfatin/Nampt: an adipokine with cardiovascular impact

T Romacho, CF Sánchez-Ferrer… - Mediators of …, 2013 - Wiley Online Library
Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors
termed adipokines. Visfatin was initially identified as a novel adipokine with insulin‐mimetic …

Aptamer-functionalized capacitive biosensors

S Weaver, MH Mohammadi, N Nakatsuka - Biosensors and Bioelectronics, 2023 - Elsevier
The growing use of aptamers as target recognition elements in label-free biosensing
necessitates corresponding transducers that can be used in relevant environments. While …

[PDF][PDF] Adipokines and cardiovascular disease: A comprehensive review.

A Smekal, J Vaclavik - … Papers of the Medical Faculty of …, 2017 - biomed.papers.upol.cz
Adipokines are peptides that signal the functional status of adipose tissue to the brain and
other target organs. In adipose tissue dysfunction, adipokine secretion is altered, and this …

Immobilization-free screening of aptamers assisted by graphene oxide

JW Park, R Tatavarty, DW Kim, HT Jung… - Chemical …, 2012 - pubs.rsc.org
Graphene oxide (GO) has the ability to separate free short ssDNA in heterogeneous
solution. This feature is applied as a label free platform for screening of aptamers that bind to …

[HTML][HTML] Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach

PL Prieto-Hontoria, P Pérez-Matute… - … et Biophysica Acta (BBA …, 2011 - Elsevier
Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary,
lifestyle and environmental factors, which favors a chronic positive energy balance, leading …

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease

AA Kei, TD Filippatos, V Tsimihodimos, MS Elisaf - Metabolism, 2012 - Elsevier
The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein
metabolism and the potential effects on the risk of cardiovascular disease (CVD). We …

11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?

P Anagnostis, N Katsiki, F Adamidou, VG Athyros… - Metabolism, 2013 - Elsevier
OBJECTIVE: Metabolic syndrome (MetS) and Cushing's syndrome share common features.
It has been proposed that increased glucocorticoid activity at peripheral tissues may play a …

[HTML][HTML] Polydatin for treating atherosclerotic diseases: a functional and mechanistic overview

M Wu, X Li, S Wang, S Yang, R Zhao, Y Xing… - Biomedicine & …, 2020 - Elsevier
With the advancement of science and technology, the living standards of human beings
have continuously improved, but the incidence and mortality from atherosclerosis worldwide …

Cardiovascular benefits of bariatric surgery in morbidly obese patients

VG Athyros, K Tziomalos, A Karagiannis… - obesity …, 2011 - Wiley Online Library
Morbid obesity is associated with increased morbidity and represents a major healthcare
problem with increasing incidence worldwide. Bariatric surgery is considered an effective …

Visfatin and subclinical atherosclerosis in type 2 diabetes: Impact of cardiovascular drugs

K Kärberg, A Forbes, M Lember - Medicina, 2023 - mdpi.com
Background and Objectives: The role of adipokines in the development of atherosclerosis in
type 2 diabetes (T2DM) has not yet been fully elucidated. The effects of drugs on adipokine …